US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LB Pharmaceuticals

49.10

+0.89001.85%

Volume:33.37K

Turnover:1.64M

Market Cap:1.58B

PE:-16.43

High:50.16

Open:48.70

Low:48.50

Close:48.21

52wk High:50.16

52wk Low:13.36

Shares:32.26M

Float Shares:21.62M

Volume Ratio:0.71

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.9880

EPS(LYR):-3.1329

ROE:-50.00%

ROA:-29.98%

PB:4.77

PE(LYR):-15.67

Loading ...

Overview Company News Filings

Lb Pharmaceuticals Announces Publication in Jama Psychiatry of Results From Phase 2 Nova-1 Trial of Lb-102 in Schizophrenia

THOMSON REUTERS

LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know

LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM

LB Pharmaceuticals Initiated at Buy by Craig-Hallum

LB Pharmaceuticals initiated with a Buy at Craig-Hallum

LB Pharmaceuticals CEO to present at Needham Virtual Healthcare Conference

LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference

LB Pharmaceuticals files to sell 4.78M shares of common stock for holders

U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings

LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.

Benzinga Earnings

LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)

LB Pharmaceuticals FY2025 net loss narrows 60.06% to $25 million; research and development expenses fall 67.38% to $17 million

Lb Pharmaceuticals Inc - Q4 Net Loss per Share $0.45

THOMSON REUTERS

Press Release: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Lb Pharmaceuticals Inc - Topline Data Expected in Second Half of 2027

THOMSON REUTERS

Lb Pharmaceuticals Initiates Pivotal Phase 3 Trial (Nova-2) for Lb-102 in Patients With Schizophrenia

THOMSON REUTERS

LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

LB Pharmaceuticals director Zachary Prensky to retire from board at 2026 annual meeting

LB Pharmaceuticals adds neuroscience leader to board, governance

LB Pharmaceuticals appoints Robert Lenz to board

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LBRX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LBRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","market":"US","secType":"STK","nameCN":"LB Pharmaceuticals","latestPrice":49.1,"timestamp":1787668589679,"preClose":48.21,"halted":0,"volume":33369,"delay":0,"changeRate":0.01846090022816844,"floatShares":21621800,"shares":32259175,"eps":-2.988,"marketStatus":"Trading","change":0.89,"latestTime":"08-25 10:36:36 EDT","open":48.7,"high":50.16,"low":48.5,"amount":1637169.4989719999,"amplitude":0.034433,"askPrice":49.49,"askSize":200,"bidPrice":49.06,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-2.988,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1757563200000,"exchange":"NASDAQ","adjPreClose":48.21,"preHourTrading":{"tag":"盘前","latestPrice":49.99,"preClose":48.21,"latestTime":"09:04 EDT","volume":7,"amount":343.49,"timestamp":1787663087050,"change":1.78,"changeRate":0.036922,"amplitude":0.030906},"postHourTrading":{"tag":"盘后","latestPrice":48.21,"preClose":48.21,"latestTime":"19:30 EDT","volume":1229,"amount":59262.11,"timestamp":1787614207179,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.705968,"impliedVol":0.6497,"impliedVolPercentile":0.377},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LBRX\",,,,,undefined,":{"symbol":"LBRX","floatShares":21621800,"roa":"-29.98%","roe":"-50.00%","lyrEps":-3.132945,"volumeRatio":0.705968,"shares":32259175,"dividePrice":0,"high":50.16,"amplitude":0.034433,"preClose":48.21,"low":48.5,"week52Low":13.36,"pbRate":"4.77","week52High":50.16,"institutionHeld":0,"latestPrice":49.1,"committee":-0.777778,"eps":-2.988,"divideRate":0,"volume":33369,"delay":0,"ttmEps":-2.988,"open":48.7,"prevYearClose":22.26,"prevWeekClose":47.62,"prevMonthClose":40.08,"prevQuarterClose":32.455,"fiveDayClose":48.77,"twentyDayClose":34.94,"sixtyDayClose":27.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LBRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"LBRX","fiscalQuarterEnding":"2026/06","expectedEps":-0.84,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-1.71},{"market":"US","date":"2026-05-12","symbol":"LBRX","fiscalQuarterEnding":"2026/03","expectedEps":-0.75,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.67},{"market":"US","date":"2026-03-26","symbol":"LBRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774497600000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LBRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LBRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1784779200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LBRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LBRX","date":"2026-08-24","current":-16.134538,"percent":0.797468,"low":-37.407457,"twenty":-31.993865,"median":-24.857779,"eighty":-17.84015,"high":-0.410019,"avg":-24.312143,"sd":7.577604,"marketCap":1536181913},"quantilePoints":[{"date":"2025-09-12","current":-13.187639,"twenty":-10.632115,"median":-6.798829,"eighty":-2.965543,"marketCap":388099031},{"date":"2025-09-19","current":-12.217088,"twenty":-12.798201,"median":-12.438246,"eighty":-12.070666,"marketCap":359536683},{"date":"2025-09-26","current":-11.40109,"twenty":-12.682283,"median":-12.163705,"eighty":-11.408716,"marketCap":335522685},{"date":"2025-10-03","current":-11.790024,"twenty":-12.394014,"median":-12.03406,"eighty":-11.475827,"marketCap":346968609},{"date":"2025-10-10","current":-11.927294,"twenty":-12.217088,"median":-11.973051,"eighty":-11.471251,"marketCap":351008347},{"date":"2025-10-17","current":-12.506882,"twenty":-12.401641,"median":-12.018808,"eighty":-11.491079,"marketCap":368065019},{"date":"2025-10-24","current":-12.079817,"twenty":-12.247593,"median":-12.026434,"eighty":-11.561239,"marketCap":355496945},{"date":"2025-10-31","current":-12.415368,"twenty":-12.43367,"median":-12.041687,"eighty":-11.652753,"marketCap":365371860},{"date":"2025-11-07","current":-18.511527,"twenty":-12.493155,"median":-12.14464,"eighty":-11.774771,"marketCap":348090759},{"date":"2025-11-14","current":-20.046619,"twenty":-12.715838,"median":-12.201836,"eighty":-11.777822,"marketCap":376956619},{"date":"2025-11-21","current":-21.244034,"twenty":-16.587413,"median":-12.217088,"eighty":-11.811377,"marketCap":399472820},{"date":"2025-11-28","current":-23.934856,"twenty":-18.511527,"median":-12.278098,"eighty":-11.89679,"marketCap":450071024},{"date":"2025-12-05","current":-25.899155,"twenty":-20.625145,"median":-12.354359,"eighty":-11.912042,"marketCap":487007713},{"date":"2025-12-12","current":-27.217658,"twenty":-21.714928,"median":-12.472564,"eighty":-11.927294,"marketCap":511800833},{"date":"2025-12-19","current":-26.50459,"twenty":-23.934856,"median":-12.598395,"eighty":-11.934921,"marketCap":498392309},{"date":"2025-12-26","current":-29.599034,"twenty":-25.317938,"median":-12.735666,"eighty":-11.971526,"marketCap":556580244},{"date":"2026-01-02","current":-29.948841,"twenty":-26.033696,"median":-12.811928,"eighty":-12.003556,"marketCap":563158010},{"date":"2026-01-09","current":-27.984542,"twenty":-26.736001,"median":-17.717835,"eighty":-12.027959,"marketCap":526221321},{"date":"2026-01-16","current":-28.76488,"twenty":-26.943194,"median":-18.511527,"eighty":-12.038636,"marketCap":540894800},{"date":"2026-01-23","current":-31.724783,"twenty":-27.597063,"median":-20.046619,"eighty":-12.056939,"marketCap":596552825},{"date":"2026-01-30","current":-28.482344,"twenty":-28.30475,"median":-20.93459,"eighty":-12.092019,"marketCap":535581989},{"date":"2026-02-06","current":-32.101498,"twenty":-28.673392,"median":-21.418938,"eighty":-12.137776,"marketCap":603636573},{"date":"2026-02-13","current":-32.760749,"twenty":-28.899421,"median":-22.367452,"eighty":-12.188109,"marketCap":616033133},{"date":"2026-02-20","current":-32.558938,"twenty":-29.179266,"median":-23.692682,"eighty":-12.201836,"marketCap":612238268},{"date":"2026-02-27","current":-32.5993,"twenty":-29.599034,"median":-24.876643,"eighty":-12.203361,"marketCap":612997241},{"date":"2026-03-06","current":-31.684421,"twenty":-30.30403,"median":-25.616619,"eighty":-12.210987,"marketCap":595793852},{"date":"2026-03-13","current":-33.554542,"twenty":-31.627914,"median":-25.899155,"eighty":-12.217088,"marketCap":630959603},{"date":"2026-03-20","current":-32.276402,"twenty":-31.988483,"median":-26.370049,"eighty":-12.224714,"marketCap":606925456},{"date":"2026-03-27","current":-24.621582,"twenty":-31.988483,"median":-26.625677,"eighty":-12.26437,"marketCap":620586972},{"date":"2026-04-02","current":-24.902627,"twenty":-31.966957,"median":-26.235508,"eighty":-12.300976,"marketCap":627670720},{"date":"2026-04-10","current":-26.388153,"twenty":-31.886233,"median":-26.156251,"eighty":-12.33148,"marketCap":665113391},{"date":"2026-04-17","current":-28.385582,"twenty":-31.84587,"median":-26.235508,"eighty":-12.354359,"marketCap":715458604},{"date":"2026-04-24","current":-35.011617,"twenty":-31.993865,"median":-26.565134,"eighty":-12.415368,"marketCap":882467800},{"date":"2026-05-01","current":-36.076352,"twenty":-32.168769,"median":-26.669198,"eighty":-12.438246,"marketCap":909304449},{"date":"2026-05-08","current":-36.38353,"twenty":-32.30331,"median":-26.814034,"eighty":-12.506882,"marketCap":917046871},{"date":"2026-05-15","current":-23.123601,"twenty":-32.316764,"median":-26.760218,"eighty":-12.583143,"marketCap":900733639},{"date":"2026-05-22","current":-20.613207,"twenty":-32.30331,"median":-26.667619,"eighty":-12.598395,"marketCap":802946256},{"date":"2026-05-29","current":-20.2672,"twenty":-32.30331,"median":-26.565134,"eighty":-12.6289,"marketCap":789468229},{"date":"2026-06-05","current":-21.275774,"twenty":-32.281784,"median":-26.235508,"eighty":-12.715838,"marketCap":828755242},{"date":"2026-06-12","current":-21.010748,"twenty":-32.254875,"median":-25.973152,"eighty":-12.741767,"marketCap":818431648},{"date":"2026-06-18","current":-22.122388,"twenty":-32.201059,"median":-25.758446,"eighty":-12.784474,"marketCap":861733392},{"date":"2026-06-26","current":-22.821765,"twenty":-32.168769,"median":-25.603165,"eighty":-13.037355,"marketCap":888976212},{"date":"2026-07-02","current":-23.476971,"twenty":-32.141861,"median":-25.394457,"eighty":-14.887526,"marketCap":914498432},{"date":"2026-07-10","current":-24.838915,"twenty":-32.079972,"median":-25.197689,"eighty":-17.661739,"marketCap":967550238},{"date":"2026-07-17","current":-22.519929,"twenty":-32.026155,"median":-24.876643,"eighty":-18.127213,"marketCap":877218784},{"date":"2026-07-24","current":-25.486758,"twenty":-31.993865,"median":-24.857779,"eighty":-18.396949,"marketCap":992785692},{"date":"2026-07-31","current":-30.110006,"twenty":-31.988483,"median":-25.029051,"eighty":-18.623718,"marketCap":1172875066},{"date":"2026-08-07","current":-35.46944,"twenty":-32.036919,"median":-25.243817,"eighty":-19.236335,"marketCap":1381641093},{"date":"2026-08-14","current":-16.667021,"twenty":-32.036919,"median":-25.197689,"eighty":-18.062763,"marketCap":1428113677},{"date":"2026-08-21","current":-17.781418,"twenty":-31.993865,"median":-24.876643,"eighty":-17.822455,"marketCap":1523600835},{"date":"2026-08-24","current":-17.928248,"twenty":-31.993865,"median":-24.857779,"eighty":-17.84015,"marketCap":1536181913}],"updateTime":1787655945225},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LBRX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629027128","title":"Lb Pharmaceuticals Announces Publication in Jama Psychiatry of Results From Phase 2 Nova-1 Trial of Lb-102 in Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2629027128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629027128?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:05","pubTimestamp":1776888302,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUABNDCBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628551217","title":"LB-102 Bipolar Depression Trial Moves Forward: What LBRX Investors Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2628551217","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628551217?lang=en_us&edition=fundamental","pubTime":"2026-04-19 00:32","pubTimestamp":1776529926,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. ($LBRX) announced an update on their ongoing clinical study. This Phase II clinical study, titled “A Randomized, Double Bl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lb-102-bipolar-depression-trial-moves-forward-what-lbrx-investors-should-know?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lb-102-bipolar-depression-trial-moves-forward-what-lbrx-investors-should-know?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LB","BK4213","LBRX","BK4233","BK4007","ISBC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627422927","title":"LB Pharmaceuticals, Inc. (LBRX) Gets a Buy from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2627422927","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627422927?lang=en_us&edition=fundamental","pubTime":"2026-04-15 05:18","pubTimestamp":1776201533,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Boobalan Pachaiyappan reiterated a Buy rating on LB Pharmaceuticals, Inc. today and set a price target of $31.00. According to Tip...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-gets-a-buy-from-roth-mkm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lb-pharmaceuticals-inc-lbrx-gets-a-buy-from-roth-mkm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4233","BK4213","LB","BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626902112","title":"LB Pharmaceuticals Initiated at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2626902112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626902112?lang=en_us&edition=fundamental","pubTime":"2026-04-11 02:04","pubTimestamp":1775844240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 14:04 ET (18:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4233","LBRX","BK4213","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626419263","title":"LB Pharmaceuticals initiated with a Buy at Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2626419263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626419263?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:33","pubTimestamp":1775820835,"startTime":"0","endTime":"0","summary":"Craig-Hallum initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $36 price target Published first on TheFly – the ultimate source...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-craig-hallum-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-initiated-with-a-buy-at-craig-hallum-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4213","LB","BK4007","LBRX","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626523130","title":"LB Pharmaceuticals CEO to present at Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626523130","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626523130?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:09","pubTimestamp":1775765371,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals CEO Heather Turner will present at Needham 25th Annual Virtual Healthcare Conference on April 16, 2026 at 11:45 a.m. ET.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2DPBLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","LBRX","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4007","SG9999014021.USD","BK4112","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626515398","title":"LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2626515398","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626515398?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:05","pubTimestamp":1775765100,"startTime":"0","endTime":"0","summary":"NEW YORK, April  09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schiz","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3271401/0/en/LB-Pharmaceuticals-Announces-Presentation-at-25th-Annual-Needham-Virtual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4137","BK4213","HCSG","LBRX","LU0128526141.USD","XBI","BK4585","XLV","BK4588","LU0029874061.USD","BK4007","LABU","LB","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625601308","title":"LB Pharmaceuticals files to sell 4.78M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601308","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625601308?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:13","pubTimestamp":1775506382,"startTime":"0","endTime":"0","summary":"16:06 EDT LB Pharmaceuticals (LBRX) files to sell 4.78M shares of common stock for holders Published first on TheFly – the ultimate source for real...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-files-to-sell-4-78m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-files-to-sell-4-78m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4233","LBRX","BK4007","LB","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845792","title":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845792","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845792?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:54","pubTimestamp":1774598066,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Brown-Forman, Chord Energy, Olaplex HoldingsMarch 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL4N40F0FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815333072.USD","GNRC","CHRD","FOXA","COP","ADP","LBRX","IE00BMPRXQ63.HKD","BIOA","NHI","BK4134","GOU","OXY","CCL","BK4561","BK4551","IT","EOG","MASI","DIS","GOOW","OLPX","LU0345769128.USD","BALY","IMMX","CTAS","OXM","DISO","GOOX","KOD","GOOP","MGTX","PRMB","KYIV","GGLL","CMC","GOOGL","UNX","PHAT","HAL","AGX","BTGO","FISV","PL","GGLS","U","SPXC","PLU","ATAI","GOOY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622089952","title":"LB Pharmaceuticals Q4 EPS $(0.45) Beats $(0.63) Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622089952","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622089952?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:30","pubTimestamp":1774557043,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals (NASDAQ:LBRX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 96.81 percent increase over losses of $(14.12) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51496123/lb-pharmaceuticals-q4-eps-0-45-beats-0-63-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622789989","title":"LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622789989?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:12","pubTimestamp":1774555927,"startTime":"0","endTime":"0","summary":"“2025 was a transformative year for LB. It began with the presentation of positive Phase 2 trial results of LB-102 in acute schizophrenia that supp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-reports-q4-eps-45c-consensus-32c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lb-pharmaceuticals-reports-q4-eps-45c-consensus-32c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622962358","title":"LB Pharmaceuticals FY2025 net loss narrows 60.06% to $25 million; research and development expenses fall 67.38% to $17 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622962358","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622962358?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:09","pubTimestamp":1774555786,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals FY2025 net loss narrows 60.06% to $25 million; research and development expenses fall 67.38% to $17 million. LB Pharmaceuticals filed a Form 8-K reporting Q4 and full-year 2025 results, including a Q4 net loss of USD 11.5 million and a full-year net loss of USD 25.2 million.Q4 R&D expense rose to USD 8.5 million, while Q4 G&A expense was USD 5.4 million.Full-year R&D expense fell 67.38% to USD 16.7 million, driven by lower spending on the Phase 2 acute schizophrenia trial that largely occurred in 2024.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL1WGQdf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899379","title":"Lb Pharmaceuticals Inc - Q4 Net Loss per Share $0.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899379?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555501,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA5YLD1Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622989619","title":"Press Release: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622989619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622989619?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:05","pubTimestamp":1774555500,"startTime":"0","endTime":"0","summary":"Reported positive results from potentially registrational Phase 2 trial of. Advanced LB-102 into late-stage development in multiple indications with initiation of. a pivotal Phase 3 NOVA-2 trial in schizophrenia, and Phase 2 ILLUMINATE-1 trial. Announced pipeline expansion with plans to initiate a Phase 2 trial of LB-102 for the. adjunctive treatment of major depressive disorder  in early 2027. Cash, cash equivalents, and investments of $295.2 million as of December 31, 2025,and proceeds from recent $100 million private placement, expected to provide cash runway into Q2 2029. The Company is building a pipeline that leverages the broad therapeutic potential of LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.-- Reported positive results in January 2025 from a robust 359 patient Phase. 2 trial  of LB-102 in acute schizophrenia. The trial met the. baseline in the Positive and Negative Syndrome Scale  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LBRX","LB","ABVC","BK4139","BK4213","BK4007","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622539073","title":"Lb Pharmaceuticals Inc - Topline Data Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2622539073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622539073?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUAPZFHS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LBRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622073533","title":"Lb Pharmaceuticals Initiates Pivotal Phase 3 Trial (Nova-2) for Lb-102 in Patients With Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073533?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUAPZFHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622739280","title":"LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia","url":"https://stock-news.laohu8.com/highlight/detail?id=2622739280","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622739280?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440000,"startTime":"0","endTime":"0","summary":"LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262125/0/en/LB-Pharmaceuticals-Initiates-Pivotal-Phase-3-Trial-NOVA-2-for-LB-102-in-Patients-with-Schizophrenia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","LBRX","BK4007","LB","PSP","BK4233"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620491089","title":"LB Pharmaceuticals director Zachary Prensky to retire from board at 2026 annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491089","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491089?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:41","pubTimestamp":1773693689,"startTime":"0","endTime":"0","summary":"Zachary Prensky told the board of LB Pharmaceuticals that he plans to retire as a director and not stand for re-election at the 2026 annual meeting. He will remain on the board and on its Nominating and Corporate Governance Committee until the conclusion of the annual meeting. Prensky is expected to provide consulting services to the company after his board term ends. LB Pharmaceuticals said a transition agreement amendment effective June 3, 2026, allows Prensky’s unvested stock options to continue vesting during the term of the amended agreement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL1GJfVv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953962","title":"LB Pharmaceuticals adds neuroscience leader to board, governance","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953962","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953962?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:49","pubTimestamp":1773146988,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals, Inc. ( ($LBRX) ) has issued an update. On March 6, 2026, LB Pharmaceuticals appointed veteran neuroscience drug development exe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-adds-neuroscience-leader-to-board-governance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lb-pharmaceuticals-adds-neuroscience-leader-to-board-governance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LBRX","BK4213","LB","BK4233","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618362582","title":"LB Pharmaceuticals appoints Robert Lenz to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2618362582","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618362582?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:01","pubTimestamp":1773057701,"startTime":"0","endTime":"0","summary":"LB Pharmaceuticals appointed Robert Lenz, M.D., Ph.D. to its board of directors. Lenz most recently served as executive vice president and head of R&D at Neumora Therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL5Nc1ry:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","NMRA","LU0314104364.USD","SG9999014039.USD","BK4007","BK4588","IE00B3QW5Z07.USD","NDAQ","LBRX","SG9999014021.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":83,"code":"91000000","status":"200"}]}}